NCT02329132View on ClinicalTrials.gov

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 28, 2018

Study Completion Date

February 28, 2018

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab

Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.

Trial Locations (1)

761-0793

Kagawa University Faculty of Medicine, Hiragi

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Kagawa University

OTHER